Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7879985,Half-life,Half-life of 8.82 hours and mean residence time of 12.18 hours were determined for MMI.,Pharmacokinetics and short-term clinicopathologic changes after intravenous administration of a high dose of methimazole in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7879985/),h,8.82,724,DB00279,Liothyronine
,7879985,mean residence time,Half-life of 8.82 hours and mean residence time of 12.18 hours were determined for MMI.,Pharmacokinetics and short-term clinicopathologic changes after intravenous administration of a high dose of methimazole in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7879985/),h,12.18,725,DB00279,Liothyronine
,2126579,half-life (t1/2),"In the euthyroid subjects, TRH blood levels had a half-life (t1/2) of 6.5 +/- 0.41 min, mean +/- SD, while t1/2 was 7.2 +/- 0.62 min in the hyperthyroid and t1/2 was 12 +/- 1.67 min (p less than 0.001) in the hypothyroid patients.",Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),min,6.5,951,DB00279,Liothyronine
,2126579,t1/2,"In the euthyroid subjects, TRH blood levels had a half-life (t1/2) of 6.5 +/- 0.41 min, mean +/- SD, while t1/2 was 7.2 +/- 0.62 min in the hyperthyroid and t1/2 was 12 +/- 1.67 min (p less than 0.001) in the hypothyroid patients.",Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),min,7.2,952,DB00279,Liothyronine
,2126579,t1/2,"In the euthyroid subjects, TRH blood levels had a half-life (t1/2) of 6.5 +/- 0.41 min, mean +/- SD, while t1/2 was 7.2 +/- 0.62 min in the hyperthyroid and t1/2 was 12 +/- 1.67 min (p less than 0.001) in the hypothyroid patients.",Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),min,12,953,DB00279,Liothyronine
,2126579,metabolic clearance rate (MCR),The metabolic clearance rate (MCR) (82.2 +/- 15.3 liters/m2/day vs. 89.8 +/- 17.2) and the volume of distribution (Vd) (7.1 +/- 4.2 liters vs. 7.3 +/- 3.4) were approximately the same in the normal subjects and in the hyperthyroid group.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),[l] / [d·m2],82.2,954,DB00279,Liothyronine
,2126579,metabolic clearance rate (MCR),The metabolic clearance rate (MCR) (82.2 +/- 15.3 liters/m2/day vs. 89.8 +/- 17.2) and the volume of distribution (Vd) (7.1 +/- 4.2 liters vs. 7.3 +/- 3.4) were approximately the same in the normal subjects and in the hyperthyroid group.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),,89.8,955,DB00279,Liothyronine
,2126579,volume of distribution (Vd),The metabolic clearance rate (MCR) (82.2 +/- 15.3 liters/m2/day vs. 89.8 +/- 17.2) and the volume of distribution (Vd) (7.1 +/- 4.2 liters vs. 7.3 +/- 3.4) were approximately the same in the normal subjects and in the hyperthyroid group.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),l,7.1,956,DB00279,Liothyronine
,2126579,volume of distribution (Vd),The metabolic clearance rate (MCR) (82.2 +/- 15.3 liters/m2/day vs. 89.8 +/- 17.2) and the volume of distribution (Vd) (7.1 +/- 4.2 liters vs. 7.3 +/- 3.4) were approximately the same in the normal subjects and in the hyperthyroid group.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),,7.3,957,DB00279,Liothyronine
,2126579,MCR,MCR (66.2 +/- 15.3 liters/m2/day) and Vd (6.2 +/- 3.3 liters) were found to be lower in the hypothyroid patients.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),[l] / [d·m2],66.2,958,DB00279,Liothyronine
,2126579,Vd,MCR (66.2 +/- 15.3 liters/m2/day) and Vd (6.2 +/- 3.3 liters) were found to be lower in the hypothyroid patients.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),l,6.2,959,DB00279,Liothyronine
,2126579,elution profile,Blood samples taken 5 min after TRH i.v. injection had an elution profile of 9.94 ml.,Single-compartment model analysis of thyrotropin-releasing hormone kinetics in hyper- and hypothyroid patients. Kinetic studies using a combined system of RIA and FPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126579/),ml,9.94,960,DB00279,Liothyronine
,2316313,molar ratio of daily production rates,"Amiodarone, an iodine containing anti-arrhythmic drug, causes a significant decrease in molar ratio of daily production rates of T3 and T4 from 0.75 in controls to 0.36 in amiodarone-treated rabbits.",Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),,0.75,10331,DB00279,Liothyronine
,2316313,molar ratio of daily production rates,"Amiodarone, an iodine containing anti-arrhythmic drug, causes a significant decrease in molar ratio of daily production rates of T3 and T4 from 0.75 in controls to 0.36 in amiodarone-treated rabbits.",Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),,0.36,10332,DB00279,Liothyronine
,2316313,metabolic clearance rates,Amiodarone treatment decreased metabolic clearance rates significantly from 0.107 +/- 0.008 in controls to 0.074 +/- 0.009 l/day in amiodarone-treated rabbits (p less than 0.05).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),[l] / [d],0.107,10333,DB00279,Liothyronine
,2316313,metabolic clearance rates,Amiodarone treatment decreased metabolic clearance rates significantly from 0.107 +/- 0.008 in controls to 0.074 +/- 0.009 l/day in amiodarone-treated rabbits (p less than 0.05).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),[l] / [d],0.074,10334,DB00279,Liothyronine
,2316313,terminal serum elimination half-life,The terminal serum elimination half-life in the two groups were similar (32.0 +/- 6.7 h in controls vs 49.2 +/- 12.4 h in amiodarone-treated).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),h,32.0,10335,DB00279,Liothyronine
,2316313,terminal serum elimination half-life,The terminal serum elimination half-life in the two groups were similar (32.0 +/- 6.7 h in controls vs 49.2 +/- 12.4 h in amiodarone-treated).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),h,49.2,10336,DB00279,Liothyronine
,3964797,systemic clearance,"During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).",Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],234,16923,DB00279,Liothyronine
,3964797,systemic clearance,"During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).",Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],172,16924,DB00279,Liothyronine
,3964797,renal clearance,This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],105,16925,DB00279,Liothyronine
,3964797,renal clearance,This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],84,16926,DB00279,Liothyronine
,3964797,nonrenal clearance,This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],130,16927,DB00279,Liothyronine
,3964797,nonrenal clearance,This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],88,16928,DB00279,Liothyronine
,3964797,half-life of elimination,Digoxin half-life of elimination was prolonged from 34 +/- 13 to 40 +/- 16 hours (p less than 0.05).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),h,34,16929,DB00279,Liothyronine
,3964797,half-life of elimination,Digoxin half-life of elimination was prolonged from 34 +/- 13 to 40 +/- 16 hours (p less than 0.05).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),h,40,16930,DB00279,Liothyronine
,19808952,area under the concentration-time curve ratios,Triiodothyronine administration significantly reduced the area under the concentration-time curve ratios for 1'-hydroxymidazolam/midazolam from 0.36 to 0.25 (P < .05) and urinary ratios of 6 beta-hydroxycortisol/free cortisol from 6.92 to 5.88 (P < .05).,Effect of thyroid hormone on the activity of CYP3A enzyme in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19808952/),,0.,21070,DB00279,Liothyronine
,3708866,plasma clearance,"The plasma clearance of T4 in rabbits treated with amiodarone for 6 weeks was significantly reduced relative to controls (64 +/- 25 vs 109 +/- 19 ml/kg per day, P less than 0.01) but the production rate was unchanged (3.8 +/- 1.8 vs 3.7 +/- 1.4 nmol/kg per day).",The effect of amiodarone on thyroxine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708866/),[ml] / [d·kg],64,23422,DB00279,Liothyronine
,3708866,plasma clearance,"The plasma clearance of T4 in rabbits treated with amiodarone for 6 weeks was significantly reduced relative to controls (64 +/- 25 vs 109 +/- 19 ml/kg per day, P less than 0.01) but the production rate was unchanged (3.8 +/- 1.8 vs 3.7 +/- 1.4 nmol/kg per day).",The effect of amiodarone on thyroxine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708866/),[ml] / [d·kg],109,23423,DB00279,Liothyronine
,3708866,production rate,"The plasma clearance of T4 in rabbits treated with amiodarone for 6 weeks was significantly reduced relative to controls (64 +/- 25 vs 109 +/- 19 ml/kg per day, P less than 0.01) but the production rate was unchanged (3.8 +/- 1.8 vs 3.7 +/- 1.4 nmol/kg per day).",The effect of amiodarone on thyroxine kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708866/),[nM] / [d·kg],3.8,23424,DB00279,Liothyronine
,3708866,production rate,"The plasma clearance of T4 in rabbits treated with amiodarone for 6 weeks was significantly reduced relative to controls (64 +/- 25 vs 109 +/- 19 ml/kg per day, P less than 0.01) but the production rate was unchanged (3.8 +/- 1.8 vs 3.7 +/- 1.4 nmol/kg per day).",The effect of amiodarone on thyroxine kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708866/),[nM] / [d·kg],3.7,23425,DB00279,Liothyronine
,7083508,indirect,"The indirect therapeutic half-life of amiodarone in seven patients, computed from the semilogarithmic plots of plasma rT3 after cessation of amiodarone therapy, ranged from 25 to 55 days (mean 35 days).",Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083508/),d,35,24046,DB00279,Liothyronine
,7083508,therapeutic half-life,"The indirect therapeutic half-life of amiodarone in seven patients, computed from the semilogarithmic plots of plasma rT3 after cessation of amiodarone therapy, ranged from 25 to 55 days (mean 35 days).",Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083508/),d,25 to 55,24047,DB00279,Liothyronine
,7083508,therapeutic half-life,"The indirect therapeutic half-life of amiodarone in seven patients, computed from the semilogarithmic plots of plasma rT3 after cessation of amiodarone therapy, ranged from 25 to 55 days (mean 35 days).",Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083508/),d,35,24048,DB00279,Liothyronine
,14697084,maximal serum concentration,"We estimate that the maximal serum concentration after the intake of the latest capsule could be 794.3 nmol/l, i.e. 397 times higher than the mean normal value.",[Triiodothyronine intoxication. A clinical and phamacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697084/),[nM] / [l],794.3,28389,DB00279,Liothyronine
,14697084,elimination half-life,The elimination half-life was 24 hours 40 minutes.,[Triiodothyronine intoxication. A clinical and phamacokinetic study]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697084/),h,24,28390,DB00279,Liothyronine
,14697084,elimination half-life,The elimination half-life was 24 hours 40 minutes.,[Triiodothyronine intoxication. A clinical and phamacokinetic study]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697084/),min,40,28391,DB00279,Liothyronine
,1726900,t1/2,The TRH-degradation curves showed similar exponential decay before and after improvement of metabolic control (t1/2: 7.6 +/- 0.4 min and 7.3 +/- 0.3 respectively; 6.5 +/- 0.4 min for the controls).,Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),min,7.6,31195,DB00279,Liothyronine
,1726900,t1/2,The TRH-degradation curves showed similar exponential decay before and after improvement of metabolic control (t1/2: 7.6 +/- 0.4 min and 7.3 +/- 0.3 respectively; 6.5 +/- 0.4 min for the controls).,Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),,7.3,31196,DB00279,Liothyronine
,1726900,t1/2,The TRH-degradation curves showed similar exponential decay before and after improvement of metabolic control (t1/2: 7.6 +/- 0.4 min and 7.3 +/- 0.3 respectively; 6.5 +/- 0.4 min for the controls).,Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),min,6.5,31197,DB00279,Liothyronine
,1726900,MCR,The MCR of exogenously administered TRH in IDDM before (65.5 +/- 8.6 l/m2/day) and after (65.0 +/- 8.9) control was not different compared to the normals (76.5 +/- 9.6).,Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),[l] / [d·m2],65.5,31198,DB00279,Liothyronine
,1726900,MCR,The MCR of exogenously administered TRH in IDDM before (65.5 +/- 8.6 l/m2/day) and after (65.0 +/- 8.9) control was not different compared to the normals (76.5 +/- 9.6).,Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),,65.0,31199,DB00279,Liothyronine
,1726900,MCR,The MCR of exogenously administered TRH in IDDM before (65.5 +/- 8.6 l/m2/day) and after (65.0 +/- 8.9) control was not different compared to the normals (76.5 +/- 9.6).,Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),[l] / [d·m2],76.5,31200,DB00279,Liothyronine
,1726900,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) in IDDM before (52.193 +/- 6.773 fmoles.ml-1.min) and after improvement of metabolic control (53.186 +/- 7.856) was slightly higher than in the healthy subjects (40.151 +/- 3.741, n.s.).",Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),[fmoles·min] / [ml],52.193,31201,DB00279,Liothyronine
,1726900,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) in IDDM before (52.193 +/- 6.773 fmoles.ml-1.min) and after improvement of metabolic control (53.186 +/- 7.856) was slightly higher than in the healthy subjects (40.151 +/- 3.741, n.s.).",Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),[fmoles·min] / [ml],53.186,31202,DB00279,Liothyronine
,1726900,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) in IDDM before (52.193 +/- 6.773 fmoles.ml-1.min) and after improvement of metabolic control (53.186 +/- 7.856) was slightly higher than in the healthy subjects (40.151 +/- 3.741, n.s.).",Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726900/),[fmoles·min] / [ml],40.151,31203,DB00279,Liothyronine
,7220596,elimination half-lives,"In male rats the elimination half-lives from the atmosphere of the exposure system amounted to 0.76h for halothane, 6.84h for enflurane and 0.64h for methoxyflurane.","Effects of thyroid dysfunction on the metabolism of halothane, enflurane and methoxyflurane in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7220596/),h,0.76,52559,DB00279,Liothyronine
,7220596,elimination half-lives,"In male rats the elimination half-lives from the atmosphere of the exposure system amounted to 0.76h for halothane, 6.84h for enflurane and 0.64h for methoxyflurane.","Effects of thyroid dysfunction on the metabolism of halothane, enflurane and methoxyflurane in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7220596/),h,6.84,52560,DB00279,Liothyronine
,7220596,elimination half-lives,"In male rats the elimination half-lives from the atmosphere of the exposure system amounted to 0.76h for halothane, 6.84h for enflurane and 0.64h for methoxyflurane.","Effects of thyroid dysfunction on the metabolism of halothane, enflurane and methoxyflurane in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7220596/),h,0.64,52561,DB00279,Liothyronine
,2898717,peak levels,"The plasma concentrations of SMS were dose-responsive and the peak levels were 1.61 +/- 0.09, 4.91 +/- 0.30 and 8.52 +/- 1.18 ng/ml, which were observed at 30, 15 and 45 min after the injection of 25, 50 and 100 micrograms of SMS, respectively.",Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898717/),[ng] / [ml],1.61,52972,DB00279,Liothyronine
,2898717,peak levels,"The plasma concentrations of SMS were dose-responsive and the peak levels were 1.61 +/- 0.09, 4.91 +/- 0.30 and 8.52 +/- 1.18 ng/ml, which were observed at 30, 15 and 45 min after the injection of 25, 50 and 100 micrograms of SMS, respectively.",Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898717/),[ng] / [ml],4.91,52973,DB00279,Liothyronine
,2898717,peak levels,"The plasma concentrations of SMS were dose-responsive and the peak levels were 1.61 +/- 0.09, 4.91 +/- 0.30 and 8.52 +/- 1.18 ng/ml, which were observed at 30, 15 and 45 min after the injection of 25, 50 and 100 micrograms of SMS, respectively.",Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898717/),[ng] / [ml],8.52,52974,DB00279,Liothyronine
,2898717,plasma disappearance half-time,Mean plasma disappearance half-time of SMS was estimated to be 110 +/- 3 min.,Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898717/),min,110,52975,DB00279,Liothyronine
,2924068,steady state distribution volume,The steady state distribution volume of ajmaline decreased from 4.81 l kg-1 in control rats to 3.80 l kg-1 in hyperthyroid rats and the total body blood clearance was slightly higher in hyperthyroid rats than in control rats.,Pharmacokinetics and dromotropic activity of ajmaline in rats with hyperthyroidism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924068/),[l] / [kg],4.81,65240,DB00279,Liothyronine
,2924068,steady state distribution volume,The steady state distribution volume of ajmaline decreased from 4.81 l kg-1 in control rats to 3.80 l kg-1 in hyperthyroid rats and the total body blood clearance was slightly higher in hyperthyroid rats than in control rats.,Pharmacokinetics and dromotropic activity of ajmaline in rats with hyperthyroidism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924068/),[l] / [kg],3.80,65241,DB00279,Liothyronine
,30301431,plateau time,"Furthermore, the plateau time, that is, the time-span during which the serum T3 concentration is at least half of T3 peak, increased from 4.9 to 7.7 hours in LT3- versus PZL-treated rats, respectively.",Metal Coordinated Poly-Zinc-Liothyronine Provides Stable Circulating Triiodothyronine Levels in Hypothyroid Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30301431/),h,4.9,65254,DB00279,Liothyronine
,30301431,plateau time,"Furthermore, the plateau time, that is, the time-span during which the serum T3 concentration is at least half of T3 peak, increased from 4.9 to 7.7 hours in LT3- versus PZL-treated rats, respectively.",Metal Coordinated Poly-Zinc-Liothyronine Provides Stable Circulating Triiodothyronine Levels in Hypothyroid Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30301431/),h,7.7,65255,DB00279,Liothyronine
,1900321,t1/2,"PCR, t1/2 and t1/2p were 22.1 +/- 3.4 ml/kg per min, 6.8 +/- 1.1 min and 17.3 +/- 6.7 min (means +/- S.D.) respectively in the euthyroid patients.",Pharmacokinetics of thyrotrophin-releasing hormone in patients in different thyroid states. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1900321/),[ml] / [kg·min],22.1,66960,DB00279,Liothyronine
,1900321,t1/2p,"PCR, t1/2 and t1/2p were 22.1 +/- 3.4 ml/kg per min, 6.8 +/- 1.1 min and 17.3 +/- 6.7 min (means +/- S.D.) respectively in the euthyroid patients.",Pharmacokinetics of thyrotrophin-releasing hormone in patients in different thyroid states. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1900321/),min,17.3,66961,DB00279,Liothyronine
,1900321,t1/2,The t1/2 was 5.6 min in the hyperthyroid patients compared with 9.4 min in the hypothyroid patients.,Pharmacokinetics of thyrotrophin-releasing hormone in patients in different thyroid states. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1900321/),min,5.6,66962,DB00279,Liothyronine
,1900321,t1/2,The t1/2 was 5.6 min in the hyperthyroid patients compared with 9.4 min in the hypothyroid patients.,Pharmacokinetics of thyrotrophin-releasing hormone in patients in different thyroid states. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1900321/),min,9.4,66963,DB00279,Liothyronine
,1900321,t1/2t,The calculated t1/2t was 6.5 min in the euthyroid patients.,Pharmacokinetics of thyrotrophin-releasing hormone in patients in different thyroid states. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1900321/),min,6.5,66964,DB00279,Liothyronine
,1487553,area under the curve (AUC) (0 to 48 hours),"Statistically significant differences for area under the curve (AUC) (0 to 48 hours) (formulation A, 159.9 +/- 9.4 micrograms-hour/dL; formulation B, 193.4 +/- 10.1 micrograms-hour/dL) and maximum peak plasma concentration (Cmax) (formulation A, 5.91 +/- .34; formulation B, 7.12 +/- .32) also were demonstrated.",A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid and Levoxine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487553/),[μgrams-hour] / [dl],159.9,70580,DB00279,Liothyronine
,1487553,area under the curve (AUC) (0 to 48 hours),"Statistically significant differences for area under the curve (AUC) (0 to 48 hours) (formulation A, 159.9 +/- 9.4 micrograms-hour/dL; formulation B, 193.4 +/- 10.1 micrograms-hour/dL) and maximum peak plasma concentration (Cmax) (formulation A, 5.91 +/- .34; formulation B, 7.12 +/- .32) also were demonstrated.",A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid and Levoxine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487553/),[μgrams-hour] / [dl],193.4,70581,DB00279,Liothyronine
,1487553,maximum peak plasma concentration (Cmax),"Statistically significant differences for area under the curve (AUC) (0 to 48 hours) (formulation A, 159.9 +/- 9.4 micrograms-hour/dL; formulation B, 193.4 +/- 10.1 micrograms-hour/dL) and maximum peak plasma concentration (Cmax) (formulation A, 5.91 +/- .34; formulation B, 7.12 +/- .32) also were demonstrated.",A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid and Levoxine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487553/),,5.91,70582,DB00279,Liothyronine
,1487553,maximum peak plasma concentration (Cmax),"Statistically significant differences for area under the curve (AUC) (0 to 48 hours) (formulation A, 159.9 +/- 9.4 micrograms-hour/dL; formulation B, 193.4 +/- 10.1 micrograms-hour/dL) and maximum peak plasma concentration (Cmax) (formulation A, 5.91 +/- .34; formulation B, 7.12 +/- .32) also were demonstrated.",A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid and Levoxine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487553/),,7.12,70583,DB00279,Liothyronine
,3435693,clearance,"2. Saliva theophylline clearance (mean +/- s.d. 5.8 +/- 2.1l h-1) was closely related to total plasma theophylline clearance (mean 3.6 +/- 1.2l h-1) (r = 0.958, n = 19, P less than 0.001).",Determinants of free theophylline clearance in asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435693/),[l] / [h],5.8,97098,DB00279,Liothyronine
,3435693,total plasma,"2. Saliva theophylline clearance (mean +/- s.d. 5.8 +/- 2.1l h-1) was closely related to total plasma theophylline clearance (mean 3.6 +/- 1.2l h-1) (r = 0.958, n = 19, P less than 0.001).",Determinants of free theophylline clearance in asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435693/),[l] / [h],3.6,97099,DB00279,Liothyronine
,3435693,clearance,"2. Saliva theophylline clearance (mean +/- s.d. 5.8 +/- 2.1l h-1) was closely related to total plasma theophylline clearance (mean 3.6 +/- 1.2l h-1) (r = 0.958, n = 19, P less than 0.001).",Determinants of free theophylline clearance in asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435693/),[l] / [h],3.6,97100,DB00279,Liothyronine
,3435693,clearance,"3. Saliva theophylline clearance was closely related (r = 0.967, n = 19, P less than 0.001) and numerically very similar to the free plasma theophylline clearance (mean 5.8 +/- 1.9l h-1) (mean difference = 0.06 +/- 0.12 s.e. mean).",Determinants of free theophylline clearance in asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435693/),[l] / [h],5.8,97101,DB00279,Liothyronine
,31364488,time to maximum serum concentration,"PK analysis indicates a time to maximum serum concentration of 1.8 ± 0.32 hours and two distinct phases of linear elimination, with a fast distribution phase and slow elimination phases with half-lives of 2.3 ± 0.11 hours and 22.9 ± 7.7 hours, supporting a two-compartment model.",Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364488/),h,1.8,98591,DB00279,Liothyronine
,31364488,half-lives,"PK analysis indicates a time to maximum serum concentration of 1.8 ± 0.32 hours and two distinct phases of linear elimination, with a fast distribution phase and slow elimination phases with half-lives of 2.3 ± 0.11 hours and 22.9 ± 7.7 hours, supporting a two-compartment model.",Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364488/),h,2.3,98592,DB00279,Liothyronine
,31364488,half-lives,"PK analysis indicates a time to maximum serum concentration of 1.8 ± 0.32 hours and two distinct phases of linear elimination, with a fast distribution phase and slow elimination phases with half-lives of 2.3 ± 0.11 hours and 22.9 ± 7.7 hours, supporting a two-compartment model.",Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364488/),h,22.9,98593,DB00279,Liothyronine
,4110897,fractional turnover rate (kT(3)),"The normal mean T(3) fractional turnover rate (kT(3)) was 0.68 (half-life = 1.0 days), increased in toxic Graves' disease patients to 1.10 (half-life = 0.63 days), and decreased in primary hypothyroid patients to 0.50 (half-life = 1.38 days).",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),,0.68,101893,DB00279,Liothyronine
,4110897,half-life,"The normal mean T(3) fractional turnover rate (kT(3)) was 0.68 (half-life = 1.0 days), increased in toxic Graves' disease patients to 1.10 (half-life = 0.63 days), and decreased in primary hypothyroid patients to 0.50 (half-life = 1.38 days).",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),d,1.0,101894,DB00279,Liothyronine
,4110897,half-life,"The normal mean T(3) fractional turnover rate (kT(3)) was 0.68 (half-life = 1.0 days), increased in toxic Graves' disease patients to 1.10 (half-life = 0.63 days), and decreased in primary hypothyroid patients to 0.50 (half-life = 1.38 days).",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),d,0.63,101895,DB00279,Liothyronine
,4110897,half-life,"The normal mean T(3) fractional turnover rate (kT(3)) was 0.68 (half-life = 1.0 days), increased in toxic Graves' disease patients to 1.10 (half-life = 0.63 days), and decreased in primary hypothyroid patients to 0.50 (half-life = 1.38 days).",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),,0.50,101896,DB00279,Liothyronine
,4110897,half-life,"The normal mean T(3) fractional turnover rate (kT(3)) was 0.68 (half-life = 1.0 days), increased in toxic Graves' disease patients to 1.10 (half-life = 0.63 days), and decreased in primary hypothyroid patients to 0.50 (half-life = 1.38 days).",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),d,1.38,101897,DB00279,Liothyronine
,4110897,T(3) distribution space,The mean T(3) distribution space in normal subjects was 38.4 liters.,Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),l,38.4,101898,DB00279,Liothyronine
,4110897,serum T(3) concentration,The normal serum T(3) concentration was estimated by radioimmunoassay to be 0.106 mug/100 ml.,Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),[μg] / [100·ml],0.106,101899,DB00279,Liothyronine
,4110897,T(3) clearance,"Combined with the mean T(3) clearance value of 26.1 liters/day, the calculated T(3) production rate was 27.6 mug/day.",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),[l] / [d],26.1,101900,DB00279,Liothyronine
,4110897,T(3) production rate,"Combined with the mean T(3) clearance value of 26.1 liters/day, the calculated T(3) production rate was 27.6 mug/day.",Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),[μg] / [d],27.6,101901,DB00279,Liothyronine
,4110897,T(3),The mean T(3) production rate increased to 201 mug/day in thyrotoxic Graves' disease patients and was reduced to 7.6 mug/day in primary hypothyroid subjects.,Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),[μg] / [d],201,101902,DB00279,Liothyronine
,4110897,production rate,The mean T(3) production rate increased to 201 mug/day in thyrotoxic Graves' disease patients and was reduced to 7.6 mug/day in primary hypothyroid subjects.,Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),[μg] / [d],201,101903,DB00279,Liothyronine
,4110897,production rate,The mean T(3) production rate increased to 201 mug/day in thyrotoxic Graves' disease patients and was reduced to 7.6 mug/day in primary hypothyroid subjects.,Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),[μg] / [d],7.6,101904,DB00279,Liothyronine
,4110897,ratio of T(3) to,The ratio of T(3) to T(4) production rate in normal subjects was 0.31 and was unchanged in patients with altered TBG values.,Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4110897/),,0,101905,DB00279,Liothyronine
,9679085,plasma clearance rates,"However, plasma clearance rates (PCR, 5.37 mL/h . 100 g body wt) and plasma appearance rates (PAR3 = PCR x [T3] plasma = 36.3 ng/h . 100 g body wt) were quite different than these indices in rat and human and 5 to 50 times larger than values reported for rainbow trout.","3,5,3'-Triiodothyronine (T3) clearance and T3-glucuronide (T3G) appearance kinetics in plasma of freshwater-reared male tilapia, Oreochromis mossambicus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679085/),[ml] / [100·h],5.37,102390,DB00279,Liothyronine
,24694613,FT4 level,"The FT4 level during the administration of suppositories was significantly lower than that during the administration of tablets (0.657±0.183 ng/dL vs. 1.25±0.51 ng/dL, p=0.034).",Clinical efficacy and pharmacokinetics of levothyroxine suppository in patients with hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694613/),[ng] / [dl],0.657,102724,DB00279,Liothyronine
,24694613,FT4 level,"The FT4 level during the administration of suppositories was significantly lower than that during the administration of tablets (0.657±0.183 ng/dL vs. 1.25±0.51 ng/dL, p=0.034).",Clinical efficacy and pharmacokinetics of levothyroxine suppository in patients with hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694613/),[ng] / [dl],1.25,102725,DB00279,Liothyronine
,12193309,time to peak levels (T(max)),"The pharmacokinetic study revealed earlier time to peak levels (T(max)) and significantly greater maximal peak levels (C(max)) in group 1 than in group 2, (85.71 +/- 12.12 minutes vs. 172.5 +/- 26.24 minutes for T(max) and 3.89 +/- 0.34 vs. 2.01 +/- 0.38 microg/mL, p < 0.05 for C(max), respectively).",Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193309/),min,85.71,107871,DB00279,Liothyronine
,12193309,T(max),"The pharmacokinetic study revealed earlier time to peak levels (T(max)) and significantly greater maximal peak levels (C(max)) in group 1 than in group 2, (85.71 +/- 12.12 minutes vs. 172.5 +/- 26.24 minutes for T(max) and 3.89 +/- 0.34 vs. 2.01 +/- 0.38 microg/mL, p < 0.05 for C(max), respectively).",Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193309/),min,172.5,107872,DB00279,Liothyronine
,12193309,T(max),"The pharmacokinetic study revealed earlier time to peak levels (T(max)) and significantly greater maximal peak levels (C(max)) in group 1 than in group 2, (85.71 +/- 12.12 minutes vs. 172.5 +/- 26.24 minutes for T(max) and 3.89 +/- 0.34 vs. 2.01 +/- 0.38 microg/mL, p < 0.05 for C(max), respectively).",Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193309/),[μg] / [ml],2.01,107873,DB00279,Liothyronine
,12193309,C(max),"The pharmacokinetic study revealed earlier time to peak levels (T(max)) and significantly greater maximal peak levels (C(max)) in group 1 than in group 2, (85.71 +/- 12.12 minutes vs. 172.5 +/- 26.24 minutes for T(max) and 3.89 +/- 0.34 vs. 2.01 +/- 0.38 microg/mL, p < 0.05 for C(max), respectively).",Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193309/),[μg] / [ml],3.89,107874,DB00279,Liothyronine
,12193309,C(max),"The pharmacokinetic study revealed earlier time to peak levels (T(max)) and significantly greater maximal peak levels (C(max)) in group 1 than in group 2, (85.71 +/- 12.12 minutes vs. 172.5 +/- 26.24 minutes for T(max) and 3.89 +/- 0.34 vs. 2.01 +/- 0.38 microg/mL, p < 0.05 for C(max), respectively).",Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193309/),[μg] / [ml],2.01,107875,DB00279,Liothyronine
,12193309,area under the curve,"However, the area under the curve (635.16 +/- 105.71 vs.",Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193309/),,635.16,107876,DB00279,Liothyronine
,2588936,cross-reactivity,"An anti-3,5,3'-triiodothyroacetic acid antibody was obtained in rabbits, using 3,5,3'-triiodothyroacetic acid coupled to hemocyanin and diazotized benzidine as antigen (cross-reactivity with T4, T3, tetraiodothyroacetic acid was 0.2, 1.1, and 5%, respectively).","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),%,0.2,121017,DB00279,Liothyronine
,2588936,cross-reactivity,"An anti-3,5,3'-triiodothyroacetic acid antibody was obtained in rabbits, using 3,5,3'-triiodothyroacetic acid coupled to hemocyanin and diazotized benzidine as antigen (cross-reactivity with T4, T3, tetraiodothyroacetic acid was 0.2, 1.1, and 5%, respectively).","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),%,1.1,121018,DB00279,Liothyronine
,2588936,cross-reactivity,"An anti-3,5,3'-triiodothyroacetic acid antibody was obtained in rabbits, using 3,5,3'-triiodothyroacetic acid coupled to hemocyanin and diazotized benzidine as antigen (cross-reactivity with T4, T3, tetraiodothyroacetic acid was 0.2, 1.1, and 5%, respectively).","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),%,5,121019,DB00279,Liothyronine
,2588936,half-life,"The half-life of 3,5,3'-triiodothyroacetic acid was 6 h 22 min +/- 29 min, the volume of distribution was 114 +/- 9 1/70 kg, and the plasma clearance rate was 298 +/- 141.(70 kg)-1.day-1.","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),h,6,121020,DB00279,Liothyronine
,2588936,half-life,"The half-life of 3,5,3'-triiodothyroacetic acid was 6 h 22 min +/- 29 min, the volume of distribution was 114 +/- 9 1/70 kg, and the plasma clearance rate was 298 +/- 141.(70 kg)-1.day-1.","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),min,22,121021,DB00279,Liothyronine
,2588936,volume of distribution,"The half-life of 3,5,3'-triiodothyroacetic acid was 6 h 22 min +/- 29 min, the volume of distribution was 114 +/- 9 1/70 kg, and the plasma clearance rate was 298 +/- 141.(70 kg)-1.day-1.","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),[1] / [70·kg],114,121022,DB00279,Liothyronine
,2588936,plasma clearance rate,"The half-life of 3,5,3'-triiodothyroacetic acid was 6 h 22 min +/- 29 min, the volume of distribution was 114 +/- 9 1/70 kg, and the plasma clearance rate was 298 +/- 141.(70 kg)-1.day-1.","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),1/[d·kg],298,121023,DB00279,Liothyronine
,2588936,potency ratio,"In conclusion, TSH inhibition by 3,5,3'-triiodothyroacetic acid is similar to T3, with a potency ratio of 1 to 18.","Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2588936/),,1 to 18,121024,DB00279,Liothyronine
,427223,half-life,"The half-life of physiologically radioiodinated asialothyroglobulins was about 6 min, while that of chemically radioiodinated asialothyroglobulin was about 12 min.",Clearance of circulating desialylated thyroglobulins in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427223/),min,6,124698,DB00279,Liothyronine
,427223,half-life,"The half-life of physiologically radioiodinated asialothyroglobulins was about 6 min, while that of chemically radioiodinated asialothyroglobulin was about 12 min.",Clearance of circulating desialylated thyroglobulins in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427223/),min,12,124699,DB00279,Liothyronine
,4032047,RAIU,"Conditions modeled included radioactive iodine uptake (RAIU) values of 0%, 1%, 5%, 15% and 25%, and RAIU of 15% combined with various degrees of pharmacologic block of thyroidal RAIU.",Radiation dosimetry of radioiodinated thyroid hormones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032047/),%,15,127485,DB00279,Liothyronine
,28741453,maximum concentration (Cmax),"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[mg] / [l],2.09,136631,DB00279,Liothyronine
,28741453,maximum concentration (Cmax),"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[mg] / [l],1.78,136632,DB00279,Liothyronine
,28741453,area under the curve,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[h·mg] / [l],68.1,136633,DB00279,Liothyronine
,28741453,area under the curve,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[h·mg] / [l],64.3,136634,DB00279,Liothyronine
,28741453,time to Cmax,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,4.00,136635,DB00279,Liothyronine
,28741453,time to Cmax,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,4.02,136636,DB00279,Liothyronine
,28741453,half-life,Mean (%CV) half-life was 24.0 (25.3) and 25.7 (21.0) hours.,No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,24.0,136637,DB00279,Liothyronine
,28741453,half-life,Mean (%CV) half-life was 24.0 (25.3) and 25.7 (21.0) hours.,No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,25.7,136638,DB00279,Liothyronine
,15553108,Cmax,"The levothyroxine mean Cmax were 112.0+/-17.3 ng/ml, 113.4+/-18.5 ng/ ml and 111.3+/-15.1 ng/ml, while the mean AUC0-24 were 2263.7+/-332.8 ng x h/ ml, 2307.3+/-351.3 ng x h/ml and 2286.1+/-331.0 ng x h/ml for the test and reference tablets as well as for the oral solution, respectively.",Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553108/),[ng] / [ml],112.0,138903,DB00279,Liothyronine
,15553108,Cmax,"The levothyroxine mean Cmax were 112.0+/-17.3 ng/ml, 113.4+/-18.5 ng/ ml and 111.3+/-15.1 ng/ml, while the mean AUC0-24 were 2263.7+/-332.8 ng x h/ ml, 2307.3+/-351.3 ng x h/ml and 2286.1+/-331.0 ng x h/ml for the test and reference tablets as well as for the oral solution, respectively.",Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553108/),[ng] / [ml],113.4,138904,DB00279,Liothyronine
,15553108,Cmax,"The levothyroxine mean Cmax were 112.0+/-17.3 ng/ml, 113.4+/-18.5 ng/ ml and 111.3+/-15.1 ng/ml, while the mean AUC0-24 were 2263.7+/-332.8 ng x h/ ml, 2307.3+/-351.3 ng x h/ml and 2286.1+/-331.0 ng x h/ml for the test and reference tablets as well as for the oral solution, respectively.",Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553108/),[ng] / [ml],111.3,138905,DB00279,Liothyronine
,15553108,AUC0-24,"The levothyroxine mean Cmax were 112.0+/-17.3 ng/ml, 113.4+/-18.5 ng/ ml and 111.3+/-15.1 ng/ml, while the mean AUC0-24 were 2263.7+/-332.8 ng x h/ ml, 2307.3+/-351.3 ng x h/ml and 2286.1+/-331.0 ng x h/ml for the test and reference tablets as well as for the oral solution, respectively.",Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553108/),[h·ng] / [ml],2263.7,138906,DB00279,Liothyronine
,15553108,AUC0-24,"The levothyroxine mean Cmax were 112.0+/-17.3 ng/ml, 113.4+/-18.5 ng/ ml and 111.3+/-15.1 ng/ml, while the mean AUC0-24 were 2263.7+/-332.8 ng x h/ ml, 2307.3+/-351.3 ng x h/ml and 2286.1+/-331.0 ng x h/ml for the test and reference tablets as well as for the oral solution, respectively.",Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553108/),[h·ng] / [ml],2307.3,138907,DB00279,Liothyronine
,15553108,AUC0-24,"The levothyroxine mean Cmax were 112.0+/-17.3 ng/ml, 113.4+/-18.5 ng/ ml and 111.3+/-15.1 ng/ml, while the mean AUC0-24 were 2263.7+/-332.8 ng x h/ ml, 2307.3+/-351.3 ng x h/ml and 2286.1+/-331.0 ng x h/ml for the test and reference tablets as well as for the oral solution, respectively.",Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553108/),[h·ng] / [ml],2286.1,138908,DB00279,Liothyronine
,8794988,AUC,AUC (34.43 +/- 12.34 compared with 33.32 +/- 9.92 nmol h L-1).,The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794988/),[h·nM] / [l],34.43,140854,DB00279,Liothyronine
,8794988,AUC,AUC (34.43 +/- 12.34 compared with 33.32 +/- 9.92 nmol h L-1).,The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794988/),[h·nM] / [l],33.32,140855,DB00279,Liothyronine
,8794988,CLapp,CLapp (36.30 +/- 12.89 compared with 37.51 +/- 11.16 mL h-1) and half-life (7.50 +/- 1.39 compared with 6.40 +/- 0.96 h) were not significantly different in the control rats compared with the cyclophosphamide-treated rats.,The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794988/),[ml] / [h],36.30,140856,DB00279,Liothyronine
,8794988,CLapp,CLapp (36.30 +/- 12.89 compared with 37.51 +/- 11.16 mL h-1) and half-life (7.50 +/- 1.39 compared with 6.40 +/- 0.96 h) were not significantly different in the control rats compared with the cyclophosphamide-treated rats.,The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794988/),[ml] / [h],37.51,140857,DB00279,Liothyronine
,8794988,half-life,CLapp (36.30 +/- 12.89 compared with 37.51 +/- 11.16 mL h-1) and half-life (7.50 +/- 1.39 compared with 6.40 +/- 0.96 h) were not significantly different in the control rats compared with the cyclophosphamide-treated rats.,The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794988/),h,7.50,140858,DB00279,Liothyronine
,8794988,half-life,CLapp (36.30 +/- 12.89 compared with 37.51 +/- 11.16 mL h-1) and half-life (7.50 +/- 1.39 compared with 6.40 +/- 0.96 h) were not significantly different in the control rats compared with the cyclophosphamide-treated rats.,The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794988/),h,6.40,140859,DB00279,Liothyronine
,12656658,basal,"In the pharmacokinetics study, basal serum concentration of Se (75+/-6 microg/l) was within the reference range (70-125 microg/l), it promptly increased at 2 h, peaked at 4 h (147+/-17 microg/l; P<0.0001) and it was abundant in serum at 24 h.",Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12656658/),[μg] / [l],75,151472,DB00279,Liothyronine
,3371148,elimination half-time,"Although there were intraindividual variations, the mean PTU elimination half-time did not change from the hyperthyroid state (1.47 h) to the euthyroid state (1.53 h).",Pharmacokinetics of propylthiouracil in children and adolescents with Graves' disease in the hyperthyroid and euthyroid states. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371148/),h,1.47,152955,DB00279,Liothyronine
,3371148,elimination half-time,"Although there were intraindividual variations, the mean PTU elimination half-time did not change from the hyperthyroid state (1.47 h) to the euthyroid state (1.53 h).",Pharmacokinetics of propylthiouracil in children and adolescents with Graves' disease in the hyperthyroid and euthyroid states. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371148/),h,1.53,152956,DB00279,Liothyronine
,3371148,Ka,The mean Ka when hyperthyroid (2.12 h-1) was significantly increased (p less than 0.005) compared to when euthyroid (1.00 h-1).,Pharmacokinetics of propylthiouracil in children and adolescents with Graves' disease in the hyperthyroid and euthyroid states. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371148/),1/[h],2.12,152957,DB00279,Liothyronine
,3371148,Ka,The mean Ka when hyperthyroid (2.12 h-1) was significantly increased (p less than 0.005) compared to when euthyroid (1.00 h-1).,Pharmacokinetics of propylthiouracil in children and adolescents with Graves' disease in the hyperthyroid and euthyroid states. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371148/),1/[h],1.00,152958,DB00279,Liothyronine
,9099387,area under the curve,"The change in thyroid status from euthyroid to hyperthyroid caused a significant (P < 0.05), but small reduction in propranolol area under the curve (19,932 +/- 7,900 min.micrograms/L vs 15,911 +/- 1,400 min.micrograms/L) after i.v. administration.",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[min·μg] / [l],"19,932",158740,DB00279,Liothyronine
,9099387,area under the curve,"The change in thyroid status from euthyroid to hyperthyroid caused a significant (P < 0.05), but small reduction in propranolol area under the curve (19,932 +/- 7,900 min.micrograms/L vs 15,911 +/- 1,400 min.micrograms/L) after i.v. administration.",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[min·μg] / [l],"15,911",158741,DB00279,Liothyronine
,9099387,area under the curve,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[min·μg] / [l],"105,430",158742,DB00279,Liothyronine
,9099387,area under the curve,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[min·μg] / [l],"226,811",158743,DB00279,Liothyronine
,9099387,peak serum propranolol concentration,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[μg] / [l],651,158744,DB00279,Liothyronine
,9099387,peak serum propranolol concentration,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[μg] / [l],1191,158745,DB00279,Liothyronine
,9099387,fractional absorption,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),%,57,158746,DB00279,Liothyronine
,9099387,fractional absorption,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),%,137,158747,DB00279,Liothyronine
,9099387,total body clearance,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[ml] / [kg·min],58,158748,DB00279,Liothyronine
,9099387,total body clearance,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[ml] / [kg·min],30,158749,DB00279,Liothyronine
,9099387,arrival time,Mean arrival time after oral dosing was significantly lengthened by hyperthyroidism (100 +/- 38 minutes vs 157 +/- 71 minutes).,Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),min,100,158750,DB00279,Liothyronine
,9099387,arrival time,Mean arrival time after oral dosing was significantly lengthened by hyperthyroidism (100 +/- 38 minutes vs 157 +/- 71 minutes).,Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),min,157,158751,DB00279,Liothyronine
,2748253,elimination half-life,"The mean elimination half-life of T4 in 7 patients with multiple serum concentrations was 2.8 +/- 0.4 days, whereas the mean elimination half-life of triiodothyronine was 6 +/- 1.7 days.",Acute thyroxine ingestion in pediatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748253/),d,2.8,159098,DB00279,Liothyronine
,2748253,elimination half-life,"The mean elimination half-life of T4 in 7 patients with multiple serum concentrations was 2.8 +/- 0.4 days, whereas the mean elimination half-life of triiodothyronine was 6 +/- 1.7 days.",Acute thyroxine ingestion in pediatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748253/),d,6,159099,DB00279,Liothyronine
,2074718,recoveries,"The recoveries of thyroxine and 3,5,3'-triiodothyronine (T3) were 96% and 101%, respectively.",A simple method for the separation and quantitation of radiolabeled thyroid hormones in thyroxine clearance studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2074718/),%,96,161870,DB00279,Liothyronine
,2074718,recoveries,"The recoveries of thyroxine and 3,5,3'-triiodothyronine (T3) were 96% and 101%, respectively.",A simple method for the separation and quantitation of radiolabeled thyroid hormones in thyroxine clearance studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2074718/),%,101,161871,DB00279,Liothyronine
,16965241,cumulative excretion,"The mean cumulative excretion of dithiocarbamates as a fraction of dose was very similar in cohorts A and B (17.8 +/- 8.6% and 19.6 +/- 11.7% of dose, respectively) and very much higher and more consistent in cohort C (70.6 +/- 2.0% of dose).","Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16965241/),%,17.8,162915,DB00279,Liothyronine
,16965241,cumulative excretion,"The mean cumulative excretion of dithiocarbamates as a fraction of dose was very similar in cohorts A and B (17.8 +/- 8.6% and 19.6 +/- 11.7% of dose, respectively) and very much higher and more consistent in cohort C (70.6 +/- 2.0% of dose).","Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16965241/),%,19.6,162916,DB00279,Liothyronine
,16965241,cumulative excretion,"The mean cumulative excretion of dithiocarbamates as a fraction of dose was very similar in cohorts A and B (17.8 +/- 8.6% and 19.6 +/- 11.7% of dose, respectively) and very much higher and more consistent in cohort C (70.6 +/- 2.0% of dose).","Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16965241/),%,70.6,162917,DB00279,Liothyronine
,831089,half-life,"Cortisol half-life was prolonged from 60 to 78 minutes (P less than 0.01), and metabolic clearance rate was decreased from 359 to 177 liters per day (P less than 0.001).",Cortisol secretion and metabolism in anorexia nervosa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),min,60 to 78,171705,DB00279,Liothyronine
,831089,metabolic clearance rate,"Cortisol half-life was prolonged from 60 to 78 minutes (P less than 0.01), and metabolic clearance rate was decreased from 359 to 177 liters per day (P less than 0.001).",Cortisol secretion and metabolism in anorexia nervosa. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),[l] / [d],359 to 177,171706,DB00279,Liothyronine
,831089,tetrahy,"These findings, as well as the increased tetrahydrocortisol/tetrahydrocortisone ratio (1.2 vs 0.65, P less than 0.01), also appear in hypothyroid patients.",Cortisol secretion and metabolism in anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),,1.2,171707,DB00279,Liothyronine
,831089,tetrahy,"These findings, as well as the increased tetrahydrocortisol/tetrahydrocortisone ratio (1.2 vs 0.65, P less than 0.01), also appear in hypothyroid patients.",Cortisol secretion and metabolism in anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),,0.65,171708,DB00279,Liothyronine
,831089,ratio,"These findings, as well as the increased tetrahydrocortisol/tetrahydrocortisone ratio (1.2 vs 0.65, P less than 0.01), also appear in hypothyroid patients.",Cortisol secretion and metabolism in anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),,1.2,171709,DB00279,Liothyronine
,831089,ratio,"These findings, as well as the increased tetrahydrocortisol/tetrahydrocortisone ratio (1.2 vs 0.65, P less than 0.01), also appear in hypothyroid patients.",Cortisol secretion and metabolism in anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),,0.65,171710,DB00279,Liothyronine
,10526245,V(d),"In addition, the V(d) (16.7 +/- 5.9/l vs 30.6 +/- 0.6/l; P < 0.0005) and PCR (2.0 +/- 0.80 l/min vs 3.3 +/- 0.25 l/min; P <0. 0005) were found statistically lowered in patients than in controls, whereas FCR (0.119 +/- 0.01 permin vs 0.110 +/- 0.01 per min; P < 0. 025) was found increased in patients as opposed to controls.",Changes in metabolism of TRH in euthyroid sick syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526245/),1/[l],16.7,177986,DB00279,Liothyronine
,10526245,V(d),"In addition, the V(d) (16.7 +/- 5.9/l vs 30.6 +/- 0.6/l; P < 0.0005) and PCR (2.0 +/- 0.80 l/min vs 3.3 +/- 0.25 l/min; P <0. 0005) were found statistically lowered in patients than in controls, whereas FCR (0.119 +/- 0.01 permin vs 0.110 +/- 0.01 per min; P < 0. 025) was found increased in patients as opposed to controls.",Changes in metabolism of TRH in euthyroid sick syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526245/),1/[l],30.6,177987,DB00279,Liothyronine
,10526245,V(d),"In addition, the V(d) (16.7 +/- 5.9/l vs 30.6 +/- 0.6/l; P < 0.0005) and PCR (2.0 +/- 0.80 l/min vs 3.3 +/- 0.25 l/min; P <0. 0005) were found statistically lowered in patients than in controls, whereas FCR (0.119 +/- 0.01 permin vs 0.110 +/- 0.01 per min; P < 0. 025) was found increased in patients as opposed to controls.",Changes in metabolism of TRH in euthyroid sick syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526245/),[l] / [min],2.0,177988,DB00279,Liothyronine
,10526245,V(d),"In addition, the V(d) (16.7 +/- 5.9/l vs 30.6 +/- 0.6/l; P < 0.0005) and PCR (2.0 +/- 0.80 l/min vs 3.3 +/- 0.25 l/min; P <0. 0005) were found statistically lowered in patients than in controls, whereas FCR (0.119 +/- 0.01 permin vs 0.110 +/- 0.01 per min; P < 0. 025) was found increased in patients as opposed to controls.",Changes in metabolism of TRH in euthyroid sick syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526245/),[l] / [min],3.3,177989,DB00279,Liothyronine
,10526245,FCR,"In addition, the V(d) (16.7 +/- 5.9/l vs 30.6 +/- 0.6/l; P < 0.0005) and PCR (2.0 +/- 0.80 l/min vs 3.3 +/- 0.25 l/min; P <0. 0005) were found statistically lowered in patients than in controls, whereas FCR (0.119 +/- 0.01 permin vs 0.110 +/- 0.01 per min; P < 0. 025) was found increased in patients as opposed to controls.",Changes in metabolism of TRH in euthyroid sick syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526245/),permin,0.119,177990,DB00279,Liothyronine
,10526245,FCR,"In addition, the V(d) (16.7 +/- 5.9/l vs 30.6 +/- 0.6/l; P < 0.0005) and PCR (2.0 +/- 0.80 l/min vs 3.3 +/- 0.25 l/min; P <0. 0005) were found statistically lowered in patients than in controls, whereas FCR (0.119 +/- 0.01 permin vs 0.110 +/- 0.01 per min; P < 0. 025) was found increased in patients as opposed to controls.",Changes in metabolism of TRH in euthyroid sick syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526245/),1/[min],0.110,177991,DB00279,Liothyronine
,10526245,t(1/2),The t(1/2) of exogenously administered TRH was increased in ESS compared with controls (7.2 +/- 0.7 min vs 6.3 +/- 0.6 min; P <0.005).,Changes in metabolism of TRH in euthyroid sick syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526245/),min,7.2,177992,DB00279,Liothyronine
,10526245,t(1/2),The t(1/2) of exogenously administered TRH was increased in ESS compared with controls (7.2 +/- 0.7 min vs 6.3 +/- 0.6 min; P <0.005).,Changes in metabolism of TRH in euthyroid sick syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10526245/),min,6.3,177993,DB00279,Liothyronine
,10736287,length of hospital stay,The median length of hospital stay was 7 days.,Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736287/),d,7,182586,DB00279,Liothyronine
,10736287,free T(3) level,The mean free T(3) level was 316+/-67 pg/dL after then administration of a placebo.,Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736287/),[pg] / [dl],316,182587,DB00279,Liothyronine
,10736287,peak free T(3),"Patients who received T(3) had mean peak free T(3) levels of 972+/-88, 1351+/-299, and 1869+/-281 pg/dL for the dosages of 0.4, 0.6, and 0.8 microg/kg, respectively.",Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736287/),[pg] / [dl],972,182588,DB00279,Liothyronine
,10736287,peak free T(3),"Patients who received T(3) had mean peak free T(3) levels of 972+/-88, 1351+/-299, and 1869+/-281 pg/dL for the dosages of 0.4, 0.6, and 0.8 microg/kg, respectively.",Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736287/),[pg] / [dl],1351,182589,DB00279,Liothyronine
,10736287,peak free T(3),"Patients who received T(3) had mean peak free T(3) levels of 972+/-88, 1351+/-299, and 1869+/-281 pg/dL for the dosages of 0.4, 0.6, and 0.8 microg/kg, respectively.",Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736287/),[pg] / [dl],1869,182590,DB00279,Liothyronine
,10736287,half-life,The calculated half-life of T(3) was 7 hours.,Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10736287/),h,7,182591,DB00279,Liothyronine
,591624,MCR,"Serum T3 concentrations decreased strikingly during starvation, from 145 +/- 7 ng/dl (mean +/- SE) to 66 +/- 9 ng/dl (P < 0.001), while the mean MCR of T3 was unchanged, with the result that T3 degradation or production rates were markedly decreased (36.4 +/- 4.5 μg/d vs. 11.2 +/- 0.7 μg/d; P < 0.001).",Effect of starvation on the production and metabolism of thyroxine and triiodothyronine in euthyroid obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/591624/),[μg] / [d],36.4,185826,DB00279,Liothyronine
,591624,degradation,"Serum T3 concentrations decreased strikingly during starvation, from 145 +/- 7 ng/dl (mean +/- SE) to 66 +/- 9 ng/dl (P < 0.001), while the mean MCR of T3 was unchanged, with the result that T3 degradation or production rates were markedly decreased (36.4 +/- 4.5 μg/d vs. 11.2 +/- 0.7 μg/d; P < 0.001).",Effect of starvation on the production and metabolism of thyroxine and triiodothyronine in euthyroid obese patients. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/591624/),[μg] / [d],36.4,185827,DB00279,Liothyronine
,591624,production rates,"Serum T3 concentrations decreased strikingly during starvation, from 145 +/- 7 ng/dl (mean +/- SE) to 66 +/- 9 ng/dl (P < 0.001), while the mean MCR of T3 was unchanged, with the result that T3 degradation or production rates were markedly decreased (36.4 +/- 4.5 μg/d vs. 11.2 +/- 0.7 μg/d; P < 0.001).",Effect of starvation on the production and metabolism of thyroxine and triiodothyronine in euthyroid obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/591624/),[μg] / [d],11.2,185828,DB00279,Liothyronine
,17631545,specific activities,"Mean radiochemical and product yields and purities were 90%, 75%, and 90% at mean specific activities of 3.9 MBq/microg (105 microCi/microg) for the (111)In-labeled SHALs.","Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631545/),[Mbq] / [μg],3.9,186717,DB00279,Liothyronine
,17631545,specific activities,"Mean radiochemical and product yields and purities were 90%, 75%, and 90% at mean specific activities of 3.9 MBq/microg (105 microCi/microg) for the (111)In-labeled SHALs.","Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631545/),[μci] / [μg],105,186718,DB00279,Liothyronine
,17259789,Cmax,"Study 1: after administration of T4-Ibsa oral solution, Cmax was 14.26+/-0.61 microg/dl, AUC0-t was 282.70 +/-14.29 microg/dl/h, Tmax was 2.71+/-0.25 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[μg] / [dl],14.26,188677,DB00279,Liothyronine
,17259789,AUC0-t,"Study 1: after administration of T4-Ibsa oral solution, Cmax was 14.26+/-0.61 microg/dl, AUC0-t was 282.70 +/-14.29 microg/dl/h, Tmax was 2.71+/-0.25 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[μg] / [dl·h],282.70,188678,DB00279,Liothyronine
,17259789,Tmax,"Study 1: after administration of T4-Ibsa oral solution, Cmax was 14.26+/-0.61 microg/dl, AUC0-t was 282.70 +/-14.29 microg/dl/h, Tmax was 2.71+/-0.25 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),h,2.71,188679,DB00279,Liothyronine
,17259789,Cmax,"After administration of Eutirox 100 tablets, Cmax was 14.34+/-0.59 microg/dl, AUC0-t was 279.42+/-9.59 microg/dl/h and Tmax was 2.65+/-0.23 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[μg] / [dl],14.34,188680,DB00279,Liothyronine
,17259789,AUC0-t,"After administration of Eutirox 100 tablets, Cmax was 14.34+/-0.59 microg/dl, AUC0-t was 279.42+/-9.59 microg/dl/h and Tmax was 2.65+/-0.23 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[μg] / [dl·h],279.42,188681,DB00279,Liothyronine
,17259789,Tmax,"After administration of Eutirox 100 tablets, Cmax was 14.34+/-0.59 microg/dl, AUC0-t was 279.42+/-9.59 microg/dl/h and Tmax was 2.65+/-0.23 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),h,2.65,188682,DB00279,Liothyronine
,17259789,Cmax,"Study 2: after administration of T3-Ibsa oral solution, Cmax was 3.19+/-0.25 ng/ml, AUC0-t was 44.79+/-2.15 ng/ml/h and Tmax was 2.31+/-0.25 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[ng] / [ml],3.19,188683,DB00279,Liothyronine
,17259789,AUC0-t,"Study 2: after administration of T3-Ibsa oral solution, Cmax was 3.19+/-0.25 ng/ml, AUC0-t was 44.79+/-2.15 ng/ml/h and Tmax was 2.31+/-0.25 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[ng] / [h·ml],44.79,188684,DB00279,Liothyronine
,17259789,Tmax,"Study 2: after administration of T3-Ibsa oral solution, Cmax was 3.19+/-0.25 ng/ml, AUC0-t was 44.79+/-2.15 ng/ml/h and Tmax was 2.31+/-0.25 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),h,2.31,188685,DB00279,Liothyronine
,17259789,Cmax,"After administration of Ti-tre tablets, Cmax was 3.16+/-0.23 ng/ml, AUC0-t was 45.19+/-2.19 ng/ml/h and Tmax was 2.44+/-0.34 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[ng] / [ml],3.16,188686,DB00279,Liothyronine
,17259789,AUC0-t,"After administration of Ti-tre tablets, Cmax was 3.16+/-0.23 ng/ml, AUC0-t was 45.19+/-2.19 ng/ml/h and Tmax was 2.44+/-0.34 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),[ng] / [h·ml],45.19,188687,DB00279,Liothyronine
,17259789,Tmax,"After administration of Ti-tre tablets, Cmax was 3.16+/-0.23 ng/ml, AUC0-t was 45.19+/-2.19 ng/ml/h and Tmax was 2.44+/-0.34 h.",Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17259789/),h,2.44,188688,DB00279,Liothyronine
,8953503,relative bioavailability,"The relative bioavailability was 50, 51 and 87%, respectively, for K4M, K15M and K100LV hydroxypropylmethylcellulose matrix tablets.",In-vivo evaluation in man of a hydrophilic matrix containing propylthiouracil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8953503/),%,50,207128,DB00279,Liothyronine
,8953503,relative bioavailability,"The relative bioavailability was 50, 51 and 87%, respectively, for K4M, K15M and K100LV hydroxypropylmethylcellulose matrix tablets.",In-vivo evaluation in man of a hydrophilic matrix containing propylthiouracil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8953503/),%,51,207129,DB00279,Liothyronine
,8953503,relative bioavailability,"The relative bioavailability was 50, 51 and 87%, respectively, for K4M, K15M and K100LV hydroxypropylmethylcellulose matrix tablets.",In-vivo evaluation in man of a hydrophilic matrix containing propylthiouracil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8953503/),%,87,207130,DB00279,Liothyronine
,8430792,production rates,kg-1 x day-1) are larger than T4 production rates (2.5 micrograms.,Thyroxine and triiodothyronine distribution and metabolism in thyroxine-replaced athyreotic dogs and normal humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430792/),μg,2.5,209029,DB00279,Liothyronine
,8430792,production rates,"These findings suggest: 1) higher fractional transfer rates of T4 and T3 from serum to tissues and total serum T4 clearance rates in dogs than humans relate to lower canine serum T4 and T3 binding, and 2) parenteral L-T4 replacement doses required to achieve upper-normal serum total T4 concentrations in athyreotic dogs (5 micrograms.kg-1 x day-1) correspond to T4 production rates (6.8 micrograms.kg-1 x day-1).",Thyroxine and triiodothyronine distribution and metabolism in thyroxine-replaced athyreotic dogs and normal humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430792/),,6.8,209030,DB00279,Liothyronine
,6172233,Bioavailability,Bioavailability of these drugs varies from 80 to 95%.,Clinical pharmacokinetics of antithyroid drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),%,80 to 95,231758,DB00279,Liothyronine
,6172233,total volume of distribution,"The total volume of distribution is about 40L for methimazole and around 30L for propylthiouracil, which is about 80% protein-bound, while methimazole is virtually non-protein-bound.",Clinical pharmacokinetics of antithyroid drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),l,40,231759,DB00279,Liothyronine
,6172233,total volume of distribution,"The total volume of distribution is about 40L for methimazole and around 30L for propylthiouracil, which is about 80% protein-bound, while methimazole is virtually non-protein-bound.",Clinical pharmacokinetics of antithyroid drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),l,30,231760,DB00279,Liothyronine
,6172233,half-life,The half-life of methimazole is 3 to 5 hours with a total clearance of about 200ml/minute.,Clinical pharmacokinetics of antithyroid drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),h,3 to 5,231761,DB00279,Liothyronine
,6172233,total clearance,The half-life of methimazole is 3 to 5 hours with a total clearance of about 200ml/minute.,Clinical pharmacokinetics of antithyroid drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),[ml] / [min],200,231762,DB00279,Liothyronine
,6172233,half-life,Propylthiouracil has a half-life of 1 to 2 hours with a clearance of around 120ml/min/m2.,Clinical pharmacokinetics of antithyroid drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),h,1 to 2,231763,DB00279,Liothyronine
,6172233,clearance,Propylthiouracil has a half-life of 1 to 2 hours with a clearance of around 120ml/min/m2.,Clinical pharmacokinetics of antithyroid drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),[ml] / [m2·min],120,231764,DB00279,Liothyronine
above,6172233,peak therapeutic serum concentration,Preliminary dose-response studies with propylthiouracil suggest a peak therapeutic serum concentration of above 4 micrograms/ml in the treatment of thyrotoxicosis.,Clinical pharmacokinetics of antithyroid drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6172233/),[μg] / [ml],4,231765,DB00279,Liothyronine
,1541918,serum half-life,Analysis of the clearance curves for the bolus injection suggested a single-compartment model and a serum half-life of 7.25 min.,Serum half-life and in-vivo actions of recombinant bovine placental lactogen in the dairy cow. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1541918/),min,7.25,233851,DB00279,Liothyronine
,20447070,time 0 TSH,"No difference was observed for time 0 TSH values between L-T3 and L-T4 replacement phases (1.48 +/- 0.77 vs. 1.21 +/- 0.62 mU/l, P = 0.293) at average daily doses of 40.3 +/- 11.3 mcg L-T3 and 115.2 +/- 38.5 mcg L-T4, L-T3: L-T4 ratio 0.36 +/- 0.06.","The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),[mu] / [l],1.48,236545,DB00279,Liothyronine
,20447070,time 0 TSH,"No difference was observed for time 0 TSH values between L-T3 and L-T4 replacement phases (1.48 +/- 0.77 vs. 1.21 +/- 0.62 mU/l, P = 0.293) at average daily doses of 40.3 +/- 11.3 mcg L-T3 and 115.2 +/- 38.5 mcg L-T4, L-T3: L-T4 ratio 0.36 +/- 0.06.","The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),[mu] / [l],1.21,236546,DB00279,Liothyronine
,20447070,ratio,"No difference was observed for time 0 TSH values between L-T3 and L-T4 replacement phases (1.48 +/- 0.77 vs. 1.21 +/- 0.62 mU/l, P = 0.293) at average daily doses of 40.3 +/- 11.3 mcg L-T3 and 115.2 +/- 38.5 mcg L-T4, L-T3: L-T4 ratio 0.36 +/- 0.06.","The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),,0.36,236547,DB00279,Liothyronine
,20447070,AUC(0-60),TRH stimulation test resulted in similar L-T3 vs. L-T4 TSH responses with AUC(0-60) of 326.1 (95% CI 232.6-457.1) and 247.1 (95% CI 153.8-397.1) mU* min/l (P = 0.285); and C(max) of 6.83 (95% CI 4.88-9.55) and 5.23 (95% CI 3.31-8.3) mU/l (P = 0.383).,"The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),[min·mu] / [l],326.1,236548,DB00279,Liothyronine
,20447070,AUC(0-60),TRH stimulation test resulted in similar L-T3 vs. L-T4 TSH responses with AUC(0-60) of 326.1 (95% CI 232.6-457.1) and 247.1 (95% CI 153.8-397.1) mU* min/l (P = 0.285); and C(max) of 6.83 (95% CI 4.88-9.55) and 5.23 (95% CI 3.31-8.3) mU/l (P = 0.383).,"The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),[min·mu] / [l],247.1,236549,DB00279,Liothyronine
,20447070,C(max),TRH stimulation test resulted in similar L-T3 vs. L-T4 TSH responses with AUC(0-60) of 326.1 (95% CI 232.6-457.1) and 247.1 (95% CI 153.8-397.1) mU* min/l (P = 0.285); and C(max) of 6.83 (95% CI 4.88-9.55) and 5.23 (95% CI 3.31-8.3) mU/l (P = 0.383).,"The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),[mu] / [l],6.83,236550,DB00279,Liothyronine
,20447070,C(max),TRH stimulation test resulted in similar L-T3 vs. L-T4 TSH responses with AUC(0-60) of 326.1 (95% CI 232.6-457.1) and 247.1 (95% CI 153.8-397.1) mU* min/l (P = 0.285); and C(max) of 6.83 (95% CI 4.88-9.55) and 5.23 (95% CI 3.31-8.3) mU/l (P = 0.383).,"The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447070/),[mu] / [l],5.23,236551,DB00279,Liothyronine
,11716045,maximum,"When 1,000 microg of levothyroxine alone was given to subjects, the maximum average total T4 absorption was 837 microg (83.7% of the dose ingested) at 120 minutes.",The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11716045/),μg,837,245768,DB00279,Liothyronine
,11716045,total T4 absorption,"When 1,000 microg of levothyroxine alone was given to subjects, the maximum average total T4 absorption was 837 microg (83.7% of the dose ingested) at 120 minutes.",The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11716045/),μg,837,245769,DB00279,Liothyronine
,11716045,maximum,"When levothyroxine was coadministered with 2.0 g of calcium (as calcium carbonate), the maximum average T4 absorption decreased to 579 microg (57.9% of the dose ingested) at 240 minutes.",The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11716045/),μg,579,245770,DB00279,Liothyronine
,11716045,T4 absorption,"When levothyroxine was coadministered with 2.0 g of calcium (as calcium carbonate), the maximum average T4 absorption decreased to 579 microg (57.9% of the dose ingested) at 240 minutes.",The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11716045/),μg,579,245771,DB00279,Liothyronine
,4090911,bioavailability,"The bioavailability of T4 in 6 euthyroid controls was in median 65% (range 64-75%), and it was significantly increased both in hyperthyroidism (88% (75-99%), n = 6, P less than 0.01) and hypothyroidism (84% (67-100%), n = 6, P less than 0.02).","The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,65,246121,DB00279,Liothyronine
,4090911,bioavailability,"The bioavailability of T4 in 6 euthyroid controls was in median 65% (range 64-75%), and it was significantly increased both in hyperthyroidism (88% (75-99%), n = 6, P less than 0.01) and hypothyroidism (84% (67-100%), n = 6, P less than 0.02).","The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,88,246122,DB00279,Liothyronine
,4090911,bioavailability,"The bioavailability of T4 in 6 euthyroid controls was in median 65% (range 64-75%), and it was significantly increased both in hyperthyroidism (88% (75-99%), n = 6, P less than 0.01) and hypothyroidism (84% (67-100%), n = 6, P less than 0.02).","The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,84,246123,DB00279,Liothyronine
,4090911,bioavailability,The bioavailability of T3 in 6 euthyroid controls was in median 78% (69-99%) and significantly greater than that of T4 (P less than 0.02).,"The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,78,246124,DB00279,Liothyronine
,4090911,bioavailability,"The bioavailability was unaffected by hyperthyroidism (79% (61-98%), n = 9) and hypothyroidism (77% (66-97%), n = 7).","The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,79,246125,DB00279,Liothyronine
,4090911,bioavailability,"The bioavailability was unaffected by hyperthyroidism (79% (61-98%), n = 9) and hypothyroidism (77% (66-97%), n = 7).","The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,77,246126,DB00279,Liothyronine
,4090911,bioavailability,The clinical implication of the present study is that the bioavailability of T4 and T3 is almost identical and approximately 80% in patients with severe hypothyroidism.,"The bioavailability of thyroxine and 3,5,3'-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4090911/),%,80,246127,DB00279,Liothyronine
,3428340,kel,"Wide individual variability was found in theophylline kinetics, but the rate of elimination of theophylline was significantly higher in hyperthyroid, and lower in hypothyroid patients than in the euthyroid patients (kel = 0.155, 0.060 and 0.107 h-1, respectively).",Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428340/),1/[h],0.155,253177,DB00279,Liothyronine
,3428340,kel,"Wide individual variability was found in theophylline kinetics, but the rate of elimination of theophylline was significantly higher in hyperthyroid, and lower in hypothyroid patients than in the euthyroid patients (kel = 0.155, 0.060 and 0.107 h-1, respectively).",Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428340/),1/[h],0.060,253178,DB00279,Liothyronine
,3428340,kel,"Wide individual variability was found in theophylline kinetics, but the rate of elimination of theophylline was significantly higher in hyperthyroid, and lower in hypothyroid patients than in the euthyroid patients (kel = 0.155, 0.060 and 0.107 h-1, respectively).",Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428340/),1/[h],0.107,253179,DB00279,Liothyronine
,6806535,metabolic clearance rates,"The metabolic clearance rates and production rates for thyroxine were 21.5 +/- 0.6 ml/kg/day and 1.34 +/- 0.23 micrograms/kg/day, respectively, and T1/2(beta) = 29.6 +/- 2.0 hours.",Pituitary and thyroid function in male cynomolgus monkeys. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6806535/),[ml] / [d·kg],21.5,253484,DB00279,Liothyronine
,6806535,production rates,"The metabolic clearance rates and production rates for thyroxine were 21.5 +/- 0.6 ml/kg/day and 1.34 +/- 0.23 micrograms/kg/day, respectively, and T1/2(beta) = 29.6 +/- 2.0 hours.",Pituitary and thyroid function in male cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6806535/),[μg] / [d·kg],1.34,253485,DB00279,Liothyronine
,6806535,T1/2(beta),"The metabolic clearance rates and production rates for thyroxine were 21.5 +/- 0.6 ml/kg/day and 1.34 +/- 0.23 micrograms/kg/day, respectively, and T1/2(beta) = 29.6 +/- 2.0 hours.",Pituitary and thyroid function in male cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6806535/),h,29.6,253486,DB00279,Liothyronine
,6806535,metabolic clearance rate,"For triiodothyronine, the metabolic clearance rate was 156.6 +/- 12.0 ml/kg/day, the production rate was 0.33 +/- 0.04 micrograms/kg/day, and T1/2 (beta) was 13.3 +/- 1.3 hours.",Pituitary and thyroid function in male cynomolgus monkeys. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6806535/),[ml] / [d·kg],156.6,253487,DB00279,Liothyronine
,6806535,production rate,"For triiodothyronine, the metabolic clearance rate was 156.6 +/- 12.0 ml/kg/day, the production rate was 0.33 +/- 0.04 micrograms/kg/day, and T1/2 (beta) was 13.3 +/- 1.3 hours.",Pituitary and thyroid function in male cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6806535/),[μg] / [d·kg],0.33,253488,DB00279,Liothyronine
,6806535,T1/2 (beta),"For triiodothyronine, the metabolic clearance rate was 156.6 +/- 12.0 ml/kg/day, the production rate was 0.33 +/- 0.04 micrograms/kg/day, and T1/2 (beta) was 13.3 +/- 1.3 hours.",Pituitary and thyroid function in male cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6806535/),h,13.3,253489,DB00279,Liothyronine
,7122691,plasma half-life,The plasma half-life after the first dose averaged 0.66 h and became greater than 1 h with chronic drug therapy.,Propylthiouracil disposition in pregnant and post-partum women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7122691/),h,0.66,255004,DB00279,Liothyronine
greater,7122691,plasma half-life,The plasma half-life after the first dose averaged 0.66 h and became greater than 1 h with chronic drug therapy.,Propylthiouracil disposition in pregnant and post-partum women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7122691/),h,1,255005,DB00279,Liothyronine
,7122691,apparent volume of distribution,"The apparent volume of distribution after the first dose averaged 0.26 liter/kg, similar to nonpregnant hyperthyroid patients.",Propylthiouracil disposition in pregnant and post-partum women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7122691/),[l] / [kg],0.26,255006,DB00279,Liothyronine
<,16045952,fT4,One 9.9-year-old administered prednisone 0.5mg/kg p.o. was found to be hypothyroid (TSH: 351microIU/mL; fT4: <2pg/mL; fT3: <1pg/mL); four age-matched normal boys (aged 6.6+/-4.9 years) served as a control group.,Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[pg] / [ml],2,262136,DB00279,Liothyronine
<,16045952,fT3,One 9.9-year-old administered prednisone 0.5mg/kg p.o. was found to be hypothyroid (TSH: 351microIU/mL; fT4: <2pg/mL; fT3: <1pg/mL); four age-matched normal boys (aged 6.6+/-4.9 years) served as a control group.,Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[pg] / [ml],1,262137,DB00279,Liothyronine
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],3360,262138,DB00279,Liothyronine
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],215,262139,DB00279,Liothyronine
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],4040,262140,DB00279,Liothyronine
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],724,262141,DB00279,Liothyronine
,16045952,AUCs,"After 6 months of thyroxine replacement therapy (75microg/day), the AUCs of prednisone and prednisolone returned to normal values (prednisone: 248microg h/L; prednisolone: 528microg h/L), as did the pattern of circadian cortisol secretion.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],248,262142,DB00279,Liothyronine
,16045952,AUCs,"After 6 months of thyroxine replacement therapy (75microg/day), the AUCs of prednisone and prednisolone returned to normal values (prednisone: 248microg h/L; prednisolone: 528microg h/L), as did the pattern of circadian cortisol secretion.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],528,262143,DB00279,Liothyronine
